Xeris to Participate in Upcoming Investor Conferences

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will take part in the following events:

• 2024 Wells Fargo Healthcare Conference, Boston, MA
  • Meetings only on September 4, 2024
• H.C. Wainwright 26^th Annual Global Investor Conference, New York, NY
  • Meetings and fireside chat on September 10, 2024 at 3:30pm ET
• 2024 Cantor Global Healthcare Conference, New York, NY
  • Meetings only on September 18, 2024

Please check with each conference sponsor to arrange 1x1 meetings.

Webcast information for the fireside chat will be available at https://xerispharma.com/investor-relations.

About Xeris

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis, a proven therapy for primary periodic paralysis; and Recorlev for the treatment of endogenous Cushing’s syndrome. Xeris has a pipeline of development and partnered programs using its formulation sciences, XeriSol and XeriJect, to support long-term product development and commercial success.

Xeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow Xeris on Twitter, LinkedIn or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240822640280/en/

The Xeris Biopharma Holdings Stock at the time of publication of the news with a raise of +4,95 % to 2,542EUR on Tradegate stock exchange (21. August 2024, 22:26 Uhr).